View source: R/TwoStageSurvSurv.R
TwoStageSurvSurv | R Documentation |
The function TwoStageSurvSurv
uses a two-stage approach to estimate R^2_{trial}
. In stage 1, trial-specific Cox proportional hazard models are fitted and in stage 2 the trial-specific estimated treatment effects on T
are regressed on the trial-specific estimated treatment effects on S
(measured on the log hazard ratio scale). The user can specify whether a weighted or unweighted model should be fitted at stage 2. See the Details section below.
TwoStageSurvSurv(Dataset, Surr, SurrCens, True, TrueCens, Treat,
Trial.ID, Weighted=TRUE, Alpha=.05)
Dataset |
A |
Surr |
The name of the variable in |
SurrCens |
The name of the variable in |
True |
The name of the variable in |
TrueCens |
The name of the variable in |
Treat |
The name of the variable in |
Trial.ID |
The name of the variable in |
Weighted |
Logical. If |
Alpha |
The |
A two-stage approach is used to estimate trial-level surrogacy, following a procedure proposed by Buyse et al. (2011). In stage 1, the following trial-specific Cox proportional hazard models are fitted:
S_{ij}(t)=S_{i0}(t) exp(\alpha_{i}Z_{ij}),
T_{ij}(t)=T_{i0}(t) exp(\beta_{i}Z_{ij}),
where S_{i0}(t)
and T_{i0}(t)
are the trial-specific baseline hazard functions, Z_{ij}
is the treatment indicator for subject j
in trial i
, \mu_{Si}
, and \alpha_{i}
and \beta_{i}
are the trial-specific treatment effects on S and T, respectively.
Next, the second stage of the analysis is conducted:
\widehat{\beta_{i}}=\lambda_{0}+\lambda_{1}\widehat{\alpha_{i}}+\varepsilon_{i},
where the parameter estimates for \beta_i
, \mu_{Si}
, and \alpha_i
are based on the full model that was fitted in stage 1.
When the argument Weighted=FALSE
is used in the function call, the model that is fitted in stage 2 is an unweighted linear regression model. When a weighted model is requested (using the argument Weighted=TRUE
in the function call), the information that is obtained in stage 1 is weighted according to the number of patients in a trial.
The classical coefficient of determination of the fitted stage 2 model provides an estimate of R^2_{trial}
.
An object of class TwoStageSurvSurv
with components,
Data.Analyze |
Prior to conducting the surrogacy analysis, data of trials that do not have at least three patients per treatment arm are excluded due to estimation constraints (Burzykowski et al., 2001). |
Results.Stage.1 |
The results of stage 1 of the two-stage model fitting approach: a |
Results.Stage.2 |
An object of class |
Trial.R2 |
A |
Trial.R |
A |
Wim Van der Elst, Ariel Alonso, & Geert Molenberghs
Burzykowski, T., Molenberghs, G., Buyse, M., Geys, H., & Renard, D. (2001). Validation of surrogate endpoints in multiple randomized clinical trials with failure-time endpoints. Applied Statistics, 50, 405-422.
Buyse, M., Michiels, S., Squifflet, P., Lucchesi, K. J., Hellstrand, K., Brune, M. L., Castaigne, S., Rowe, J. M. (2011). Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. Haematologica, 96, 1106-1112.
plot.TwoStageSurvSurv
# Open Ovarian dataset
data(Ovarian)
# Conduct analysis
Results <- TwoStageSurvSurv(Dataset = Ovarian, Surr = Pfs, SurrCens = PfsInd,
True = Surv, TrueCens = SurvInd, Treat = Treat, Trial.ID = Center)
# Examine results of analysis
summary(Results)
plot(Results)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.